Immunotherapy Biomarkers

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model
Koichi Azuma, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Norikazu Matsuo, Hidenobu Ishii, Takaaki Tokito, Akihiko Kawahara, Kenta Murotani, Tetsuro Sasada, Yohei Miyagi, Tomoaki Hoshino

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004420; DOI: 10.1136/jitc-2021-004420
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
Mark A J Gorris, Lieke L van der Woude, Leonie I Kroeze, Kalijn Bol, Kiek Verrijp, Avital L Amir, Jelena Meek, Johannes Textor, Carl G Figdor, I Jolanda M de Vries

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004329; DOI: 10.1136/jitc-2021-004329
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004569; DOI: 10.1136/jitc-2022-004569
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
Joan Frigola, Caterina Carbonell, Patricia Iranzo, Nuria Pardo, Ana Callejo, Susana Cedres, Alex Martinez-Marti, Alejandro Navarro, Mireia Soleda, Jose Jimenez, Javier Hernandez-Losa, Ana Vivancos, Enriqueta Felip, Ramon Amat

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004197; DOI: 10.1136/jitc-2021-004197
Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis
Omkar Chaudhary, Diane Trotta, Kaicheng Wang, Xun Wang, Xiuping Chu, Chip Bradley, Jason Okulicz, Ryan C Maves, Karl Kronmann, Christina M Schofield, Jason M Blaylock, Yanhong Deng, Kurt A Schalper, Susan M Kaech, Brian Agan, Anuradha Ganesan, Brinda Emu

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004564; DOI: 10.1136/jitc-2022-004564
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Haizhou Wang, Yabo Zhou, Yangyang Zhang, Shilin Fang, Meng Zhang, Haiou Li, Fei Xu, Lan Liu, Jing Liu, Qiu Zhao, Fan Wang

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004302; DOI: 10.1136/jitc-2021-004302
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
Evan Rosenbaum, Cristina R Antonescu, Shaleigh Smith, Martina Bradic, Daniel Kashani, Allison L Richards, Mark Donoghue, Ciara M Kelly, Benjamin Nacev, Jason E Chan, Ping Chi, Mark A Dickson, Mary L Keohan, Mrinal M Gounder, Sujana Movva, Viswatej Avutu, Katherine Thornton, Ahmet Zehir, Anita S Bowman, Samuel Singer, William Tap, Sandra D’Angelo

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e004149; DOI: 10.1136/jitc-2021-004149
Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis
Xiaofang Xing, Jinyao Shi, Yongning Jia, Yunsheng Dou, Zhongwu Li, Bin Dong, Ting Guo, Xiaojing Cheng, Xiaomei Li, Hong Du, Ying Hu, Shuqin Jia, Jian Zhang, Ziyu Li, Jiafu Ji

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003984; DOI: 10.1136/jitc-2021-003984
eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004026; DOI: 10.1136/jitc-2021-004026
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer
Yijia Xu, Han Zeng, Kaifeng Jin, Zhaopei Liu, Yu Zhu, Le Xu, Zewei Wang, Yuan Chang, Jiejie Xu

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003416; DOI: 10.1136/jitc-2021-003416

Main menu

Immunotherapy Biomarkers

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy Biomarkers

Pages